Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in Relapsed/Refractory Follicular Lymphoma
NCT04707079Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in follicular lymphoma (FL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04707079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707079.